Clearly it is in no one’s interests for a clinical trial to fail. Whenever these high-stake activites are abandoned and drug development pathways are aborted, missed opportunities abound. Beyond the sponsor’s missed commercial opportunity, there are missed opportunities to advance … Read More
Author Archives: Bernard Vrijens
Moving clinical trials towards the value-rich model of continuous monitoring
In a clinical trial, every piece of data contributes to the overall story being told. No matter how small or seemingly insignificant, all the information that emerges over the course of the process adds rich detail to the narrative. Two … Read More
AARDEX Group and SHL Medical forge strategic alliance to interface medication adherence software with connected self-injection solutions
AARDEX Group Belgium – SHL Medical, a world-leading provider of drug delivery devices, and AARDEX Group, the global leader in medication adherence solutions, today announced their strategic partnership aimed at delivering an end-to-end solution for pharma customers seeking to demonstrate … Read More
ESPACOMP Conference: A collective opportunity to advance the science of medication adherence
It is perhaps ironic that Alexander Graham Bell, often singled out as the individual who invented the telephone, was a man who believed in the value of collective endeavour. Indeed, Bell is quoted as saying: “Great discoveries and improvements invariably … Read More
Placebo and adherence: Is a complicated relationship compromising clinical trial effectiveness?
In 1920, The Lancet published a paper authored by T.C. Graves entitled ‘Commentary on a case of hystero-epilepsy with delayed puberty: Treated with testicular extract’. While the article was not the first to mention the placebo effect, it is recognised … Read More
Digital adherence measurement in clinical trials: The era of clearer insight is already here
Among the many forces that can influence clinical trials, arguably not enough attention is paid to status quo bias. A common phenomenon, status quo bias can explain why any proposed departure from existing expectations or dominant practice can be … Read More
Enhancing Medication Adherence in Rare Disease Clinical Trials
In observance of Rare Disease Day, it is imperative to underscore the progressive strides within the domain of rare disease research. Rare diseases, characterized by their infrequent occurrence within the general populace, impose significant burdens not only on the affected … Read More
How Medication Adherence Packaging is Transforming Clinical Trials and why FDA Approves
Drug trials are conducted to evaluate the safety and efficacy of new or investigational drugs. The primary goal of drug trials is to determine if a new drug is effective in treating a particular medical condition and if it is … Read More
Why Objective and Granular Digital Adherence Monitoring is Gaining Traction in Trials.
“Objective and granular” digital adherence measures could improve trial efficiency and allow for better-informed decisions on the efficacy and safety of new drug products. That’s according to the authors of a literature review that looked at more than 100 medicines … Read More
Medication Technology: Bridging the Gap Between Drug Trials and Real World
With the current push for increased diversity in research, the medical community has accepted the challenge to make trial populations more representative of those in clinical practice. Yet poor medication adherence, which clouds the view of how drugs work in … Read More